Metabolics Pharma Announces Ent-03 Generates Sustained Weight Loss And Liver Pathology Improvements In An Animal Model For Obesity
June 27 (Reuters) -
METABOLICS PHARMA ANNOUNCES ENT-03 GENERATES SUSTAINED WEIGHT LOSS AND LIVER PATHOLOGY IMPROVEMENTS IN AN ANIMAL MODEL FOR OBESITY
METABOLICS PHARMA - A PHASE 1B CLINICAL TRIAL IS PLANNED TO INITIATE IN SECOND HALF OF 2025
Further company coverage: [ ]
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.